Literature DB >> 11034640

Human intervertebral disc cells are genetically modifiable by adenovirus-mediated gene transfer: implications for the clinical management of intervertebral disc disorders.

S H Moon1, L G Gilbertson, K Nishida, M Knaub, T Muzzonigro, P D Robbins, C H Evans, J D Kang.   

Abstract

STUDY
DESIGN: Human intervertebral disc cells were cultured in monolayer and treated with adenovirus-containing marker genes to determine the susceptibility of the cells to adenovirus-mediated gene transfer.
OBJECTIVES: To test the efficacy of the adenovirus-mediated gene transfer technique for transferring exogenous genes to human intervertebral disc cells in vitro. SUMMARY OF BACKGROUND DATA: Upregulated proteoglycan synthesis after direct in vivo adenovirus-mediated transfer of growth factor genes to the rabbit intervertebral disc has previously been reported. Before contemplating extending this approach to the treatment of human disc disease, it is necessary to demonstrate that human intervertebral disc cells are indeed susceptible to adenovirus-mediated gene transduction.
METHODS: Human intervertebral disc cells were isolated from disc tissue obtained from 15 patients during surgical disc procedures. The cells were cultured in monolayer and treated with saline containing five different doses of adenovirus carrying the lacZ gene (Ad/CMV-lacZ), saline containing adenovirus carrying the luciferase gene (Ad/CMV-luciferase), or saline alone. Transgene expression was analyzed by 5-bromo-4-chloro-3-indolyl-beta-galactosidase (X-Gal) staining and luciferase assay.
RESULTS: Adenovirus efficiently transferred lacZ and luciferase marker genes to cells from degenerated discs as well as to cells from nondegenerated discs. A minimum dose of 150 MOI Ad/CMV-lacZ was found to be sufficient to achieve transduction of approximately 100% of disc cells-regardless of patient age, sex, surgical indication, disc level, and degeneration grade. No statistically significant difference in the luciferase activities could be detected in disc cell cultures from degenerated and nondegenerated discs treated with Ad/CMV-luciferase.
CONCLUSIONS: In vitro transducibility of human intervertebral disc cells by adenovirus is relatively insensitive to disc degeneration grade. Because the rate-limiting step for successful gene therapy is the ability to transfer genes efficiently to the target tissue, the achievement of efficient gene transfer to human intervertebral disc cells(using a direct, adenovirus-mediated approach) is an important and necessary step in the development of gene therapy strategies for the management of human intervertebral disc disorders.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11034640     DOI: 10.1097/00007632-200010150-00006

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  17 in total

Review 1.  Orthopaedic applications of gene therapy.

Authors:  Martin Lind; Cody Bünger
Journal:  Int Orthop       Date:  2005-05-18       Impact factor: 3.075

2.  A preliminary in vitro study into the use of IL-1Ra gene therapy for the inhibition of intervertebral disc degeneration.

Authors:  Christine L Le Maitre; Anthony J Freemont; Judith A Hoyland
Journal:  Int J Exp Pathol       Date:  2006-02       Impact factor: 1.925

3.  Methods to monitor distribution and metabolic activity of mesenchymal stem cells following in vivo injection into nucleotomized porcine intervertebral discs.

Authors:  G W Omlor; H Bertram; K Kleinschmidt; J Fischer; K Brohm; T Guehring; M Anton; Wiltrud Richter
Journal:  Eur Spine J       Date:  2009-12-29       Impact factor: 3.134

4.  Ad/CMV- hTGF-beta1 treats rabbit intervertebral discs degeneration in vivo.

Authors:  Zirui Zhan; Zengwu Shao; Xiaoqian Xiong; Shuhua Yang; Jingyuan Du; Qixin Zheng; Hong Wang; Xiaodong Guo; Yong Liu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2004

5.  Functional probe for annulus fibrosus-targeted intervertebral disc degeneration imaging.

Authors:  Hye-Yeong Kim; Michael Mcclincy; Nam V Vo; Gwendolyn A Sowa; James D Kang; Mingfeng Bai
Journal:  J Biomed Opt       Date:  2013-10       Impact factor: 3.170

Review 6.  Biological treatment strategies for disc degeneration: potentials and shortcomings.

Authors:  Günther Paesold; Andreas G Nerlich; Norbert Boos
Journal:  Eur Spine J       Date:  2006-09-16       Impact factor: 3.134

7.  Release of active and depot GDF-5 after adenovirus-mediated overexpression stimulates rabbit and human intervertebral disc cells.

Authors:  Haili Wang; Markus Kroeber; Michael Hanke; Rainer Ries; Carsten Schmid; Wolfgang Poller; Wiltrud Richter
Journal:  J Mol Med (Berl)       Date:  2003-12-11       Impact factor: 4.599

8.  Biologic response of human intervertebral disc cells to gene therapy cocktail.

Authors:  Seong-Hwan Moon; Kotaro Nishida; Lars G Gilbertson; Hwan-Mo Lee; Hyang Kim; Ronald A Hall; Paul D Robbins; James D Kang
Journal:  Spine (Phila Pa 1976)       Date:  2008-08-01       Impact factor: 3.468

Review 9.  Biologic treatment of mild and moderate intervertebral disc degeneration.

Authors:  Elias S Vasiliadis; Spyros G Pneumaticos; Demitrios S Evangelopoulos; Athanasios G Papavassiliou
Journal:  Mol Med       Date:  2014-09-18       Impact factor: 6.354

10.  Safety assessment of intradiscal gene therapy II: effect of dosing and vector choice.

Authors:  Eric A Levicoff; Joseph S Kim; Satoshi Sobajima; Corey J Wallach; James W Larson; Paul D Robbins; Xiao Xiao; Li Juan; Gianluca Vadala; Lars G Gilbertson; James D Kang
Journal:  Spine (Phila Pa 1976)       Date:  2008-06-15       Impact factor: 3.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.